All News
Prof van Lear noted 5-10% of pts have D2T RA; the highest risk factor is low socieconomic status. D2T RA have higher comorbidities and healthcare utilization #EULAR2022 @rheumnow https://t.co/PhPjhksyI4 https://t.co/JCByho4ubk
TheDaoIndex KDAO2011 ( View Tweet)
Associations with RA-BR (n=57 cases) compared to RA-no lung disease controls (n=36)
⬆️⬆️⬆️RF level (OR 4.4)
⬆️⬆️ ACPA level (OR 3.5)
⬆️older age at RA onset (OR 1.37 per 10 years)
⬇️ BMI (OR 0.94 per kg/m2) (i.e., higher risk in underweight)
🚫 associations: sex, smoking pk-yrs
Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)
Watch: New 2022 EULAR RA Treatment Guidelines
https://t.co/mF4cKJLtbr
#EULAR2022 https://t.co/oI8p6gL0Tf
Links:
Dr. John Cush RheumNow ( View Tweet)
Nossent et al Hospitalisation with opportunistic infection twice as high in RA vs AxSpA/PsA. Has IMPROVED over biologic era. To me, suggests benefits of proper disease control on infection risk
@RheumNow
#EULAR2022 OP0274 https://t.co/cqUoRti4We https://t.co/Ozz7jH3z4N
Links:
Richard Conway RichardPAConway ( View Tweet)
More from GLORIA. Tapering pred 5mg after 2 years. Some minor increase in disease activity (DAS28 0.26) with no evidence of adrenal insufficiency. Can successfully withdraw long term steroids! @RheumNow #EULAR2022 OP0270 https://t.co/IV9iJLY22v https://t.co/ZXdwxlXorK
Links:
Richard Conway RichardPAConway ( View Tweet)
van der Pol et al from BeST study. No association with diabetes for pred use HR 0.588 (95%CI 0.285; 1.21) nor cumulative pred dose OR 1.04 (95% CI 0.978; 1.13). Higher DAS assoc with diabetes. @RheumNow #EULAR2022 OP0272 https://t.co/QVjphcD7MG https://t.co/Buj8VAIJ5x
Links:
Richard Conway RichardPAConway ( View Tweet)
Alsing et al. Dutch study. Persistent excess stroke risk in RA in biologic era. @RheumNow #EULAR2022 OP0277 https://t.co/oLmsrniKw6 https://t.co/2zDkuUzq0S
Links:
Richard Conway RichardPAConway ( View Tweet)
Are JAKi fulfilling their promises in RA? H Schulz-Koops said a survey showed rheumatologists wanted effective fast acting Rx that could be used as monotherapy. @eular_org #EULAR2022 @RheumNow https://t.co/Gdel9YnAzA
Janet Pope Janetbirdope ( View Tweet)
VIGIBASE registry RA
39000+ pts JAKi and 231000+ pts TNFi
*No increase in MACEs with JAKi 1.4% vs. 0.9%
*JAKi Increase in DVT RR 3.99
and PE RR 3.5
adjusted on age and sex
@RheumNow #OP0268 #EULAR2022 #Lupus https://t.co/hiAvKctgky
Aurelie Najm AurelieRheumo ( View Tweet)
Gilbert et al. RA assoc increased risk hospitalisation or death from COVID-19 1.53 (1.20, 1.94). RA-ILD assoc even greater risk hospitalisation or death multivariable HR 2.84 [95% CI 1.64-4.91] @RheumNow #EULAR2022 OP0251 https://t.co/h1jzAV6xNR https://t.co/7E1EzAKCDv
Links:
Richard Conway RichardPAConway ( View Tweet)
Hilarious debate #EULAR2022 between Christian Dejaco and Robert Landewe on whether telemedicine is the future of rheumatology. In amongst the trash talking, here are some highlights @RheumNow
David Liew drdavidliew ( View Tweet)
#ClinicalPearl. Why do doctors prescribe #JAKi in RA? Efficacy, fast onset, X-ray inhibition, can work as monotherapy, remission - in order of diminishing frequency BUT I will add access and oral (convenience). POS0680 @RheumNow @eular_org #EULAR2022 https://t.co/XHtNqguqvh
Janet Pope Janetbirdope ( View Tweet)
Boers et al. GLORIA trial of long term 5mg pred in RA. Titled as "favourable balance of benefit and harm". I cannot agree. 24% increase adverse events, NNH 9, for DAS28 0.37 better at 1 year, and really no difference after that. @RheumNow #EULAR2022 OP0263 https://t.co/eO4f1CjH5q https://t.co/VyyZm1QvYy
Links:
Richard Conway RichardPAConway ( View Tweet)
Deep learning can be used to distinguish seropositive RA from seronegative RA and PsA based on MRI.
Early changes in PsO may suggest a PsA-like MRI pattern may be present!
Is this how we predict which PsO -> PsA?
@RheumNow #EULAR2022 ABST#OP0292 https://t.co/NGfFkSqlaM
Robert B Chao, MD doctorRBC ( View Tweet)
#EULAR2022 POS0213
Beware of paradoxical low lipids in RA!
⭐️ETN+MTX vs MTX T2T:
Early ETN: increased in HLD, lesser LDL, differs from MTX. Correlates with clinical disease activity
@RheumNow https://t.co/c6GXadVwYN
Eric Dein ericdeinmd ( View Tweet)
#EULAR2022 POS0207
Fatigue in early RA:
⭐️Does not show direct effect between inflammation on fatigue
⭐️Suggests broader indirect effect of psychosocial aspects of wellbeing (pain, mental health, sleep, disease perception) plays larger role
@Rheumnow https://t.co/zTxk7kZRIX
Eric Dein ericdeinmd ( View Tweet)
Szekanecz et al. ORAL Surveillance. Geographic differences in MACE largely driven by history CVD and high baseline risk in North America and ROW. @RheumNow #EULAR2022 POS0110 https://t.co/cR6a7N2KP5
Richard Conway RichardPAConway ( View Tweet)
The third SARS-CoV-2 vaccine in IMID (RA, SpA, PsA, UC, CD) patients on immunosuppression improves the serologic response follow the first two vaccine doses and allowed them to close the gap compared to the two-dose vaccinated controls #EULAR2022 @RheumNow OP0192 Jyssum et al
Dr. Antoni Chan synovialjoints ( View Tweet)
#EULAR2022 POS0210
RNA sequencing in 11 RA-ILD patients vs 9 RA pts
⭐️Distinct gene expression in RA-ILD with type 1 IFN response, neutrophil activation, and degranulation and CCR1 chemokine interactions
@RheumNow
@fahidalghanim https://t.co/FIrZfzZV1C
Eric Dein ericdeinmd ( View Tweet)
#EULAR2022 OP0278:
Increase in risk of CVA compared to general population ~1.2x risk
⭐️This is unchanged between the pre-biologic (1972-1998) and the post-biologic treatment era
⭐️Interesting finding: smoking rate same over time in RA, despite decr in Norway in gen pop
@Rheumnow https://t.co/r8QsJABfvx
Eric Dein ericdeinmd ( View Tweet)
